NEW YORK — MARCH 16, 2021 — Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announces today that President and CEO Michael Feldschuh will present at Maxim Group 2021 Emerging Growth Virtual Conference to be held March 17-19, 2021, 9:00 AM – 5:00 PM EST.
Mr. Feldschuh will highlight the many recent accomplishments of the Company including accelerating revenue, groundbreaking research and product development, contracts with the US Department of Defense, grant funding through the National Institute of Health, and new prospective medical trials for the use of Daxor’s BVA-100® blood test in the management of critical care, COVID-19, and heart failure with leading institutions.
Investors can view Mr. Feldschuh’s general corporate presentation once they register for the conference, and an archived replay of the presentation will be available via the conference website. Investors can also request a one-on-one meeting with Mr. Feldschuh following the conclusion of the conference.
Event: Maxim Group’s Inaugural Emerging Virtual Conference
Date: March 17th -19th, 9:00 AM – 5:00 PM EST
Interested investors can contact Bret Shapiro at COREIR either by calling 1-516-222-2560 or emailing email@example.com.
About Daxor Corporation
Daxor Corporation (NYSE: DXR) is the global leader in blood volume measurement technology focused on blood volume testing innovation (organized as an investment company with fully-owned innovative medical instrumentation and biotechnology operations). We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology enhances hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved multiple measures of patient outcomes. Daxor’s mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com.
Investor Relations Contact:
Sr. Managing Partner, CORE IR